Precigen announces clearance of ind to initiate phase i study of prgn-2012 adenoverse™ immunotherapy in patients with recurrent respiratory papillomatosis (rrp)

Germantown, md., jan. 5, 2021 /prnewswire/ -- precigen, inc. (nasdaq: pgen), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the us food and drug administration (fda) has cleared the...
PGEN Ratings Summary
PGEN Quant Ranking